Andrew Hantel
Assistant Professor of Medicine, Harvard Medical School · Mass General Brigham
Credentials: · · · · ·
History
- Present
Mass General Brigham · University of Pennsylvania Health System
- Present
Center
Research
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
New England Journal of Medicine · 2016 · 716 citations
British Journal of Haematology · 2012 · 82 citations
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
Case report · Journal for ImmunoTherapy of Cancer · 2018 · First of 5 authors · 50 citations
31 papers
9 papers
9 papers
8 papers
7 papers
7 papers
- LM
6 papers
6 papers
Grants
- 2022–2027
Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention
National Cancer Institute · K08
Contact PI · $1.2M · Dana-Farber Cancer Inst
Clinical trials
- 2026–2029
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Principal investigator · Recruiting · Phase 1
Andrew Hantel, MD
- 2025–2027
Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
Principal investigator · Recruiting
Dana-Farber Cancer Institute
- 2025–2026
Pilot of a Trial Enrollment Diversity Dashboard
Principal investigator · Completed
Dana-Farber Cancer Institute
- 2024–2028
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
Principal investigator · Recruiting
Dana-Farber Cancer Institute